Brunner Lab

Dominguez, D; Kamphuis, S; Beyene, J; Wither, J; Harley, JB; Blanco, I; Vila-Inda, C; Brunner, H; Klein-Gitleman, M; McCurdy, D; et al. Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. Journal of Rheumatology. 2021; 48:852-858.

Aljaberi, N; Nguyen, K; Strahle, C; Merritt, A; Mathur, A; Brunner, HI. Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults. Arthritis Care and Research. 2021; 73:580-585.

Lovell, DJ; Huang, B; Chen, C; Angeles-Han, ST; Simon, TA; Brunner, HI. Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. RMD Open. 2021; 7.

Brunner, HI; Ruperto, N; Zuber, Z; Cuttica, R; Keltsev, V; Xavier, RM; Burgos-Vargas, R; Penades, IC; Silverman, ED; Espada, G; et al. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. Arthritis and Rheumatology. 2021; 73:530-541.

Quartier, P; Alexeeva, E; Constantin, T; Chasnyk, V; Wulffraat, N; Palmblad, K; Wouters, C; I Brunner, H; Marzan, K; Schneider, R; et al. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. Arthritis and Rheumatology. 2021; 73:336-346.

Ruperto, N; Brunner, HI; Ramanan, AV; Horneff, G; Cuttica, R; Henrickson, M; Anton, J; Boteanu, AL; Penades, IC; Minden, K; et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology. 2021.

Ruperto, N; Brunner, HI; Pacheco-Tena, C; Louw, I; Vega-Cornejo, G; Spindler, AJ; Kingsbury, DJ; Schmeling, H; Borzutzky, A; Cuttica, R; et al. Open-Label Phase 3 Study of Intravenous Golimumab in Patients With Polyarticular Juvenile Idiopathic Arthritis. Rheumatology. 2021.

Reighard, SD; Krishnamurthy, D; Cevik, H; Ochayon, DE; Ali, A; Seelamneni, H; Brunner, HI; Waggoner, SN. Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease. Cytotherapy. 2021; 23:37-45.

Chen, Y; Sun, L; Xu, H; Dong, M; Mizuno, T; Vinks, AA; Brunner, HI; Li, Y; Li, Z. PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. Frontiers in Pharmacology. 2020; 11.

Weiss, PF; Fuhlbrigge, RC; von Scheven, E; Lovell, DJ; Colbert, RA; Brunner, HI; PRCSG Advisory Council, the CARRA Executive Commit, . Children with enthesitis-related arthritis could benefit from treatments targeted for adults with spondyloarthritis. Arthritis Care and Research. 2020.

Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatric Rheumatology. 2020; 18.

Brunner, HI; Tzaribachev, N; Cornejo, GV; Joos, R; Gervais, E; Cimaz, R; Calvo Penades, I; Cuttica, R; Lutz, T; Quartier, P; et al. Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatric Rheumatology. 2020; 18.

DiFrancesco, MW; Lee, G; Altaye, M; Beebe, DW; Meyers-Eaton, J; Brunner, HI. Cerebral microvascular and microstructural integrity is regionally altered in patients with systemic lupus erythematosus. Arthritis Research and Therapy. 2020; 22.

Simon, TA; Harikrishnan, GP; Kawabata, H; Singhal, S; Brunner, HI; Lovell, DJ. Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study. Pediatric Rheumatology. 2020; 18.

Brunner, HI; Quartier, P; Alexeeva, E; Constantin, T; Koné-Paut, I; Marzan, K; Schneider, R; Wulffraat, NM; Chasnyk, V; Tirosh, I; et al. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. Arthritis and Rheumatology. 2020; 72:2147-2158.

Malattia, C; Ruperto, N; Pederzoli, S; Palmisani, E; Pistorio, A; Wouters, C; Dolezalova, P; Flato, B; Garay, S; Giancane, G; et al. Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. Arthritis Research and Therapy. 2020; 22.

Brunner, HI; Wong, R; Nys, M; Kou, TD; Dominique, A; Martini, A; Lovell, DJ; Ruperto, N. Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. Paediatric Drugs. 2020; 22:653-672.

Parks, CG; Wilkerson, J; Rose, KM; Faiq, A; Noroozi Farhadi, P; Long, CS; Bayat, N; Brunner, HI; Goldberg, B; McGrath, JA; et al. Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. Arthritis Care and Research. 2020; 72:1636-1644.

Brunner, HI; Nanda, K; Toth, M; Foeldvari, I; Bohnsack, J; Milojevic, D; Rabinovich, CE; Kingsbury, DJ; Marzan, K; Chalom, E; et al. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. Arthritis Care and Research. 2020; 72:1420-1430.

Smitherman, EA; Huang, B; Furnier, A; Taylor, J; Burns, MB; Brunner, HI; Morgan, EM. Quality of Care in Childhood-onset Systemic Lupus Erythematosus: Report of an Intervention to Improve Cardiovascular and Bone Health Screening. Journal of Rheumatology. 2020; 47:1506-1513.

Brunner, HI; Abud-Mendoza, C; Viola, DO; Calvo Penades, I; Levy, D; Anton, J; Calderon, JE; Chasnyk, VG; Ferrandiz, MA; Keltsev, V; et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Annals of the Rheumatic Diseases. 2020; 79:1340-1348.

Schultz, K; Divanovic, A; Towe, C; Miethke, A; Wusik, K; Hammill, A; Brunner, H. A 4-Year-Old Child with Digital Clubbing. Arthritis Care and Research. 2020.

Brunner, HI; Chen, C; Bovis, F; De Benedetti, F; Espada, G; Joos, R; Akikusa, J; Chaitow, J; Boteanu, AL; Kimura, Y; et al. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2020.

Canna, SW; Schulert, GS; de Jesus, A; Pickering, A; Brunner, H; Gadina, M; Levine, S; Goldbach-Mansky, R; Boutelle, J; Sinha, R; et al. Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Pediatric Rheumatology. 2020; 18.

Lovell, DJ; Brunner, HI; Reiff, AO; Jung, L; Jarosova, K; Nemcova, D; Mouy, R; Sandborg, C; Bohnsack, JF; Elewaut, D; et al. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. RMD Open. 2020; 6.

Reighard, SD; Cranert, SA; Rangel, KM; Ali, A; Gyurova, IE; de la Cruz-Lynch, AT; Tuazon, JA; Khodoun, MV; Kottyan, LC; Smith, DF; et al. Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells. 2020; 1.

Huang, B; Qiu, T; Chen, C; Zhang, Y; Seid, M; Lovell, D; Brunner, HI; Morgan, EM; PCATS, . Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. RMD Open. 2020; 6.

Huang, B; Qiu, T; Chen, C; Neace, A; Zhang, Y; Yue, X; Zahner, J; Adams, M; Seid, M; Lovell, D; et al. Comparative Effectiveness Research Using Electronic Health Records Data: Ensure Data Quality. . : SAGE Publications Ltd; SAGE Publications Ltd; 2020.

Cunningham, NR; Fussner, LM; Moorman, E; Aydin, PO A; Brunner, HI; Kashikar-Zuck, S. Development and pilot testing of the treatment and education approach for childhood-onset lupus (TEACH): a cognitive behavioral treatment. Pediatric Rheumatology. 2019; 17.

Leong, JY; Chen, P; Yeo, JG; Ally, F; Chua, C; Hazirah, SN; Poh, SL; Pan, L; Lai, L; Lee, ES C; et al. Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal. Annals of the Rheumatic Diseases. 2019; 78:1712-1721.

Schulert, GS; Yasin, S; Carey, B; Chalk, C; Do, T; Schapiro, AH; Husami, A; Watts, A; Brunner, HI; Huggins, J; et al. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis and Rheumatology. 2019; 71:1943-1954.

Deng, J; Chalhoub, NE; Sherwin, CM; Li, C; Brunner, HI. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 2019; 49:251-259.

Pardeo, M; Wang, J; Ruperto, N; Alexeeva, E; Chasnyk, V; Schneider, R; Horneff, G; Huppertz, H; Minden, K; Onel, K; et al. Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. Journal of Rheumatology. 2019; 46:1117-1126.

Rodriguez-Smith, J; Brunner, HI. Update on the treatment and outcome of systemic lupus erythematous in children. Current Opinion in Rheumatology. 2019; 31:464-470.

Morgan, EM; Munro, JE; Horonjeff, J; Horgan, B; Shea, B; Feldman, BM; Clairman, H; III, BC O; Thornhill, S; Strand, V; et al. Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. Journal of Rheumatology. 2019; 46:1006-1013.

Mulvihill, E; Ardoin, S; Thompson, SD; Zhou, B; Yu, GR; King, E; Singer, N; Levy, DM; Brunner, H; Wu, YL; et al. Elevated serum complement levels and higher gene copy number of complement C4B are associated with hypertension and effective response to statin therapy in childhood-onset systemic lupus erythematosus (SLE). Lupus Science and Medicine. 2019; 6.

Brunner, HI; Holland, MJ; Beresford, MW; Ardoin, SP; Appenzeller, S; Silva, CA; Flores, F; Aydin, PO A; Wenderfer, SE; Levy, DM; et al. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care and Research. 2019; 71:579-590.

Aljaberi, N; Bennett, M; Brunner, HI; Devarajan, P. Proteomic profiling of urine: implications for lupus nephritis. Expert Review of Proteomics. 2019; 16:303-313.

Angeles-Han, ST; Lo, MS; Henderson, LA; Lerman, MA; Abramson, L; Coopers, AM; Parsa, MF; Zemel, LS; Ronis, T; Beukelman, T; et al. Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. Arthritis Care and Research. 2019; 71:482-491.

Ramanan, AV; Brunner, HI; Ruperto, N; Martini, A; Cuttica, RJ; Weiss, JE; Henrickson, M; Schmeling, H; Antón, J; Minden, K; et al. 170 Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis. Rheumatology. 2019; 58.

Hinze, CH; Foell, D; Johnson, AL; Spalding, SJ; Gottlieb, BS; Morris, PW; Kimura, Y; Onel, K; Li, SC; Grom, AA; et al. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis and Rheumatology. 2019; 71:451-459.

Brunner, HI; Martini, A; Lovell, DJ; Ruperto, N; Or, PR I T; Collaborative, PR. Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. Annals of the Rheumatic Diseases. 2019; 78:162-170.

Turnier, JL; Brunner, HI; Bennett, M; Aleed, A; Gulati, G; Haffey, WD; Thornton, S; Wagner, M; Devarajan, P; Witte, D; et al. Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity. Rheumatology. 2019; 58:321-330.

Brunner, HI; Gulati, G; Klein-Gitelman, MS; Rouster-Stevens, KA; Tucker, L; Ardoin, SP; Onel, KB; Mainville, R; Turnier, J; Aydin, PO A; et al. Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. Pediatric Nephrology. 2019; 34:117-128.

Brunner, HI; Rider, LG; Kingsbury, DJ; Co, D; Schneider, R; Goldmuntz, E; Onel, KB; Giannini, EH; Lovell, DJ; Council, PR C S G A. Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology. Pediatric Rheumatology. 2018; 16.

Ruperto, N; Brunner, HI; Quartier, P; Constantin, T; Wulffraat, NM; Horneff, G; Kasapcopur, O; Schneider, R; Anton, J; Barash, J; et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Annals of the Rheumatic Diseases. 2018; 77:1710-1719.

Cooper, JC; Rouster-Stevens, K; Wright, TB; Hsu, JJ; Klein-Gitelman, MS; Ardoin, SP; Schanberg, LE; Brunner, HI; Eberhard, BA; Wagner-Weiner, L; et al. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. Pediatric Rheumatology. 2018; 16.

AlE'ed, A; Aydin, PO A; Al Mutairi, N; AlSaleem, A; Sonmez, HE; Henrickson, M; Huggins, JL; Ozen, S; Al-Mayouf, SM; Brunner, HI. Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus. Lupus Science and Medicine. 2018; 5.

Holland, MJ; Beresford, MW; Feldman, BM; Huggins, J; Norambuena, X; Silva, CA; Susic, G; Sztajnbok, F; Uziel, Y; Appenzeller, S; et al. Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care and Research. 2018; 70:1621-1629.

Lovell, DJ; Johnson, AL; Huang, B; Gottlieb, BS; Morris, PW; Kimura, Y; Onel, K; Li, SC; Grom, AA; Taylor, J; et al. Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. Arthritis and Rheumatology. 2018; 70:1508-1518.

Brunner, HI; Tzaribachev, N; Vega-Cornejo, G; Louw, I; Berman, A; Calvo Penades, I; Anton, J; Avila-Zapata, F; Cuttica, R; Horneff, G; et al. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. Arthritis and Rheumatology. 2018; 70:1144-1154.

Patel, ZH; Lu, X; Miller, D; Forney, CR; Lee, J; Lynch, A; Schroeder, C; Parks, L; Magnusen, AF; Chen, X; et al. A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Human Molecular Genetics. 2018; 27:2392-2404.

Schulert, GS; Zhang, M; Husami, A; Fall, N; Brunner, H; Zhang, K; Cron, RQ; Grom, AA. Brief Report: Novel UNC13D Intronic Variant Disrupting an NF-κB Enhancer in a Patient With Recurrent Macrophage Activation Syndrome and Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2018; 70:963-970.

Brunner, HI; Holland, M; Beresford, MW; Ardoin, SP; Appenzeller, S; Silva, CA; Flores, F; Goilav, B; Wenderfer, SE; Levy, DM; et al. American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care and Research. 2018; 70:813-822.

Buchbinder, D; Sanchez, GA M; Goldbach-Mansky, R; Brunner, H; Shulman, AI. Rash, Fever, and Pulmonary Hypertension in a 6-Year-Old Female. Arthritis Care and Research. 2018; 70:785-790.

Harry, O; Yasin, S; Brunner, H. Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. Journal of Pediatrics. 2018; 196:22-30.e2.

Lovell, DJ; Brunner, HI; Ringold, S; Weiss, PF; Martin, N; Consolaro, A; Bovis, F; Ruperto, N; Trials, PR I. The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International. 2018; 38:35-42.

Gulati, G; Brunner, HI. Environmental triggers in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 2018; 47:710-717.

Aydin, PO A; Shan, J; Brunner, HI; Mitsnefes, MM. Blood pressure control over time in childhood-onset systemic lupus erythematous. Lupus. 2018; 27:657-664.

Redel, JM; DiFrancesco, M; Vannest, J; Altaye, M; Beebe, D; Khoury, J; Dolan, LM; Lee, G; Brunner, H; Holland, S; et al. Brain gray matter volume differences in obese youth with type 2 diabetes: a pilot study. Journal of Pediatric Endocrinology and Metabolism. 2018; 31:261-268.

Fussner, L; Cunningham, N; Moorman, E; Warner, J; Watts, A; Brunner, H; Kashikar-Zuck, S. (172) Cognitive behavioral therapy protocol development for childhood-onset systemic lupus erythematosus. Pain Forum. 2018; 19.

Brunner, HI; Ruperto, N; Tzaribachev, N; Horneff, G; Chasnyk, VG; Panaviene, V; Abud-Mendoza, C; Reiff, A; Alexeeva, E; Rubio-Perez, N; et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Annals of the Rheumatic Diseases. 2018; 77:21-29.

Ruperto, N; Brunner, HI; Zuber, Z; Tzaribachev, N; Kingsbury, DJ; Foeldvari, I; Horneff, G; Smolewska, E; Vehe, RK; Hazra, A; et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatric Rheumatology. 2017; 15.

Brachat, AH; Grom, AA; Wulffraat, N; Brunner, HI; Quartier, P; Brik, R; McCann, L; Ozdogan, H; Rutkowska-Sak, L; Schneider, R; et al. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Research and Therapy. 2017; 19.

Kimura, Y; Grevich, S; Beukelman, T; Morgan, E; Nigrovic, PA; Mieszkalski, K; Graham, TB; Ibarra, M; Ilowite, N; Klein-Gitelman, M; et al. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatric Rheumatology. 2017; 15.

Langefeld, CD; Ainsworth, HC; Graham, DS C; Kelly, JA; Comeau, ME; Marion, MC; Howard, TD; Ramos, PS; Croker, JA; Morris, DL; et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications. 2017; 8.

Morgan, EM; Riebschleger, MP; Horonjeff, J; Consolaro, A; Munro, JE; Thornhill, S; Beukelman, T; Brunner, HI; Creek, EL; Harris, JG; et al. Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. Journal of Rheumatology. 2017; 44:1884-1888.

Turnier, JL; Fall, N; Thornton, S; Witte, D; Bennett, MR; Appenzeller, S; Klein-Gitelman, MS; Grom, AA; Brunner, HI. Urine S100 proteins as potential biomarkers of lupus nephritis activity. Arthritis Research and Therapy. 2017; 19.

Oni, L; Beresford, MW; Witte, D; Chatzitolios, A; Sebire, N; Abulaban, K; Shukla, R; Ying, J; Brunner, HI. Inter-observer variability of the histological classification of lupus glomerulonephritis in children. Archives de Pediatrie. 2017; 24:1335-1336.

Feldon, M; Farhadi, PN; Brunner, HI; Itert, L; Goldberg, B; Faiq, A; Wilkerson, J; Rose, KM; Rider, LG; Miller, FW; et al. Predictors of Reduced Health-Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies. Arthritis Care and Research. 2017; 69:1743-1750.

Bennett, MR; Ma, Q; Ying, J; Devarajan, P; Brunner, H. Effects of age and gender on reference levels of biomarkers comprising the pediatric Renal Activity Index for Lupus Nephritis (p-RAIL). Pediatric Rheumatology. 2017; 15.

AlE'ed, A; Vega-Fernandez, P; Muscal, E; Hinze, CH; Tucker, LB; Appenzeller, S; Bader-Meunier, B; Roth, J; Torrente-Segarra, V; Klein-Gitelman, MS; et al. Challenges of Diagnosing Cognitive Dysfunction With Neuropsychiatric Systemic Lupus Erythematosus in Childhood. Arthritis Care and Research. 2017; 69:1449-1459.

Bernatsky, S; Clarke, AE; Niaki, OZ; Labrecque, J; Schanberg, LE; Silverman, ED; Hayward, K; Imundo, L; Brunner, HI; Haines, KA; et al. Malignancy in Pediatric-onset Systemic Lupus Erythematosus. Journal of Rheumatology. 2017; 44:1484-1486.

Ruperto, N; Brunner, HI; Lovell, DJ; Martini, A. Extrapolation or controlled trials in paediatrics: the current dilemma. Archives of Disease in Childhood. 2017; 102:949-951.

Jafri, S; Ramanan, AV; De Benedetti, F; Ruperto, N; Lovell, D; Cuttica, R; Weiss, JE; Henrickson, M; Schmeling, H; Anton, J; et al. 06. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis. Rheumatology. 2017; 56.

Gulati, G; Bennett, MR; Abulaban, K; Song, H; Zhang, X; Ma, Q; Brodsky, SV; Nadasdy, T; Haffner, C; Wiley, K; et al. Prospective validation of a novel renal activity index of lupus nephritis. Lupus. 2017; 26:927-936.

Brunner, HI; Bennett, MR; Gulati, G; Abulaban, K; Klein-Gitelman, MS; Ardoin, SP; Tucker, LB; Rouster-Stevens, KA; Witte, D; Ying, J; et al. Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults. Journal of Rheumatology. 2017; 44:1239-1248.

Valieva, S; Bzarova, T; Nikishina, I; Rodionovskaya, S; Mizuta, M; Yachie, A; Sugita, Y; Okamoto, N; Shabana, K; Murata, T; et al. Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two. Pediatric Rheumatology. 2017; 15.

Conti, G; Marchetti, F; Salis, A; Caroli, F; Damonte, G; Bondet, V; Kusche, Y; Barczyk-Kahlert, K; Chiocchetti, A; Polizzi, S; et al. Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one. Pediatric Rheumatology. 2017; 15.

Papa, R; Consolaro, A; Minoia, F; Caorsi, R; Magnano, G; Gattorno, M; Ravelli, A; Pillon, R; Marafon, DP; Meli, L; et al. Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three. Pediatric Rheumatology. 2017; 15.

Phillippi, K; Hoeltzel, M; Byun Robinson, A; Kim, S; Abramson, LS; Anderson, ES; Becker, ML; Benham, H; Beukelman, T; Blier, PR; et al. Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. Journal of Pediatrics. 2017; 184:38-44.e1.

Ruperto, N; Lovell, DJ; Tzaribachev, N; Vega-Cornejo, G; Louw, I; Berman, A; Calvo, I; Cuttica, R; Horneff, G; Avila-Zapata, F; et al. O28. SUBCUTANEOUS ABATACEPT IN PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC OR NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: PHARMACOKINETICS, EFFICACY AND SAFETY. Rheumatology. 2017; 56.

Wenderfer, SE; Ruth, NM; Brunner, HI. Advances in the care of children with lupus nephritis. Pediatric Research. 2017; 81:406-414.

Gulati, G; Jones, JT; Lee, G; Altaye, M; Beebe, DW; Meyers-Eaton, J; Wiley, K; Brunner, HI; DiFrancesco, MW. Altered Blood-Brain Barrier Permeability in Patients With Systemic Lupus Erythematosus: A Novel Imaging Approach. Arthritis Care and Research. 2017; 69:299-305.

Yu, T; Enioutina, EY; Brunner, HI; Vinks, AA; Sherwin, CM. Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. Clinical Pharmacokinetics. 2017; 56:107-125.

Jones, JT; Carle, AC; Wootton, J; Liberio, B; Lee, J; Schanberg, LE; Ying, J; DeWitt, EM; Brunner, HI. Validation of Patient-Reported Outcomes Measurement Information System Short Forms for Use in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care and Research. 2017; 69:133-142.

Brunner, HI; Abulaban, KM. Pediatric and Neonatal Lupus. Pediatric Rheumatology. 2017.